Impact of Efgartigimod on INCAT Scores in CIDP: ADHERE/ADHERE+ Post Hoc Analysis

Neurologists Karissa Gable, MD, FAAN, and Jeffrey Allen, MD, discuss how treatment success in CIDP extends beyond disease stabilization, emphasizing meaningful functional improvement and patient-centered goals.

Measuring treatment response in chronic inflammatory demyelinating polyneuropathy extends beyond neurological examination alone.

While primary end points often determine whether a clinical trial meets its objectives, secondary and post hoc analyses frequently provide the clinical context that physicians need to apply those findings in practice.

For clinicians treating chronic inflammatory demyelinating polyneuropathy, numerical improvements on disability scales ultimately matter only if they translate into better function for patients.

As new therapies enter clinical practice, the questions clinicians ask often shift from whether a treatment works to how it can be used most effectively in the patients they see every day.

The treatment landscape for chronic inflammatory demyelinating polyneuropathy has changed considerably over the past several years, with targeted therapies expanding the options available to clinicians beyond traditional immunomodulatory approaches.